Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Valeant Pharmaceuticals International Inc Raises FY 2013 EPS Guidance; Reaffirms FY 2013 Revenue Guidance


Thursday, 2 May 2013 06:00am EDT 

Valeant Pharmaceuticals International Inc updated its previous cash EPS guidance and is now targeting cash EPS of $5.55 to $5.85 in fiscal 2013, despite a recent entry of Zovirax generic ointment, up from prior guidance of $5.45 to $5.75. Total revenue in the range of $4.4 to $4.8 billion. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of $5.59 on revenues of $4.6 billion for fiscal 2013.